+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06337318

Randomized Study Comparing Rituximab and Mosunetuzumab Treatments for Low Tumor Burden Follicular Lymphoma

Led by National Cancer Institute (NCI) · Updated on 2026-11-03

600

Participants Needed

288

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are comparing two treatments, rituximab and mosunetuzumab, for patients with follicular lymphoma that has a low tumor burden. This phase III trial aims to see which treatment better helps patients avoid disease progression or worsening over time. Both drugs are monoclonal antibodies targeting cancer cells, but it is unknown which one is more effective for this condition. Participants are randomly assigned to one of two groups. One group receives rituximab intravenously on day 1 of the first cycle, then rituximab with hyaluronidase subcutaneously on days 8, 15, and 22 of the first cycle and on day 1 of later cycles cycles repeat every 56 days for up to 5 cycles. The other group receives mosunetuzumab subcutaneously on days 1, 8, and 15 of the first cycle and day 1 of later cycles cycles repeat every 21 days for up to 8 cycles. During treatment, participants have CT or PETCT scans and blood samples collected. After treatment, participants are followed every 6 months for 5 years and then yearly up to 10 years. Researchers assess progression-free survival, overall survival, response rates, event-free survival, and treatment side effects. Specimens are also collected for future research. The total participation may last up to 10 years, including long-term monitoring for disease status and safety.

CONDITIONS

Brief Title

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here